Hong‐Min Liu

7.7k total citations · 1 hit paper
266 papers, 5.9k citations indexed

About

Hong‐Min Liu is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Hong‐Min Liu has authored 266 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 168 papers in Molecular Biology, 71 papers in Organic Chemistry and 60 papers in Oncology. Recurrent topics in Hong‐Min Liu's work include Epigenetics and DNA Methylation (50 papers), Histone Deacetylase Inhibitors Research (38 papers) and Ubiquitin and proteasome pathways (27 papers). Hong‐Min Liu is often cited by papers focused on Epigenetics and DNA Methylation (50 papers), Histone Deacetylase Inhibitors Research (38 papers) and Ubiquitin and proteasome pathways (27 papers). Hong‐Min Liu collaborates with scholars based in China, New Zealand and United States. Hong‐Min Liu's co-authors include Yi‐Chao Zheng, Bin Yu, Zhe‐Sheng Chen, Xiaojing Shi, Liying Ma, Dandan Shen, Jinlian Ma, Shuo Yuan, Ying Liu and Bo Wang and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Circulation Research.

In The Last Decade

Hong‐Min Liu

259 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Application and synthesis of thiazole ring in clinically approved drugs

2023 109 citations Saiqi Wang, Hong‐Min Liu et al. European Journal of Medicinal Chemistry profile →

Peers

Countries citing papers authored by Hong‐Min Liu

Since Specialization

Citations

This map shows the geographic impact of Hong‐Min Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hong‐Min Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hong‐Min Liu more than expected).

Fields of papers citing papers by Hong‐Min Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hong‐Min Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hong‐Min Liu. The network helps show where Hong‐Min Liu may publish in the future.

Co-authorship network of co-authors of Hong‐Min Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Hong‐Min Liu. A scholar is included among the top collaborators of Hong‐Min Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hong‐Min Liu. Hong‐Min Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia 2025 ·Bioorganic Chemistry ·Zhuo Qian, Yi‐Ru Bai, Wenjuan Zhou, Shengnan Zhang, Jingyue Li, Qi Sun, (unknown), (unknown), Hong‐Min Liu, Shuo Yuan, (unknown)	2
2	Association of Estimated Glomerular Filtration Rate (eGFR) and High-Sensitivity C-Reactive Protein (Hs-CRP) with the Risk of New-Onset Atrial Fibrillation in Patients with Diabetes 2025 ·Journal of Inflammation Research ·Ying Liu, Hong‐Min Liu, (unknown), (unknown), Gary Tse, Kang‐Yin Chen, Jiuchun Qiu, Shouling Wu, Ying Liu	2
3	A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect 2024 ·European Journal of Medicinal Chemistry ·Yi‐Ru Bai, Xin Yang, (unknown), (unknown), Yaodong Zhang, Li Zhou, Li Yang, Hong‐Min Liu, Shuo Yuan	5
4	Decoding CLU (Clusterin): Conquering cancer treatment resistance and immunological barriers 2024 ·International Immunopharmacology ·MAA Mamun, Yi‐Chao Zheng, Ning Wang, Bo Wang, Yu Zhang, Jing‐Ru Pang, Dandan Shen, Hong‐Min Liu, Ya Gao	4
5	Obesity and physical inactivity are associated with increased risks of cardiac conduction disease: a report from the Kailuan Cohort Study 2024 ·PubMed ·Hong‐Min Liu, (unknown), Peipei Liu, Haiyan Zhao, (unknown), (unknown), (unknown), Gregory Y.H. Lip, Shouling Wu, (unknown)	0
6	Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy 2024 ·Journal of Medicinal Chemistry ·Liang Shen, Bo Wang, Shaopeng Wang, (unknown), (unknown), Shuwu Wang, (unknown), Xing‐Jie Dai, Hong‐Min Liu	20
7	Discovery of 2-Aryl-4-aminoquinazolin-Based LSD1 Inhibitors to Activate Immune Response in Gastric Cancer 2024 ·Journal of Medicinal Chemistry ·(unknown), Shuwu Wang, Ying Zhou, Shaopeng Wang, Ya Gao, (unknown), (unknown), Saiqi Wang, Yi‐Chao Zheng, Cheng Zhang, Adil Mardinoğlu, Hong‐Min Liu, Xiaobing Chen, Xing‐Jie Dai	6
8	Discovery of neddylation E2s inhibitors with therapeutic activity 2023 ·Oncogenesis ·MAA Mamun, Ying Liu, (unknown), Yi‐Chao Zheng, Ya Gao, Jiangang Sun, Longfei Zhao, Lijuan Zhao, Hong‐Min Liu	5
9	Design, synthesis and antitumor activity evaluation of 4,6,7-trisubstituted quinazoline derivatives containing benzothiazole moiety 2023 ·Medicinal Chemistry Research ·(unknown), Ying Xu, (unknown), (unknown), (unknown), Chao Gao, (unknown), Yuandong Niu, Zhengjie Wang, Yu Ke, Hong‐Min Liu, Qiurong Zhang	2
10	New drug approvals for 2022: Synthesis and clinical applications 2023 ·Medicinal Research Reviews ·Shuo Yuan, Dandan Shen, Rui Jia, (unknown), Jian Song, Hong‐Min Liu	17
11	The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases 2023 ·European Journal of Medicinal Chemistry ·Yi‐Ru Bai, Weiguang Yang, (unknown), Dandan Shen, Shengnan Zhang, Na Li, (unknown), Saiqi Wang, Shuo Yuan, Hong‐Min Liu	23
12	Triazole-fused pyrimidines in target-based anticancer drug discovery 2023 ·European Journal of Medicinal Chemistry ·Xing‐Jie Dai, (unknown), (unknown), Ying Zhou, Ya Gao, Yi‐Chao Zheng, Huimin Liu, Hong‐Min Liu	36
13	Inhibition of lysine-specific demethylase 1 enhances the sensitivity of the chemotherapeutic drug doxorubicin in gastric cancer cell 2022 ·Molecular Biology Reports ·(unknown), Hao Pan, Junwei Wang, Wen Zhao, Hong‐Min Liu, Pengxing He	4
14	Multiple Physical Bonds Cross-Linked Strong and Tough Hydrogel with Antibacterial Ability for Wearable Strain Sensor 2022 ·ACS Applied Polymer Materials ·(unknown), Baobao Chang, Hong‐Min Liu, Xiaozhen Zhang, (unknown), Xiang Liu, (unknown), Chuntai Liu	18
15	Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor 2022 ·Acta Pharmaceutica Sinica B ·Saiqi Wang, Qiu‐Xu Teng, Shuai Wang, Zi‐Ning Lei, (unknown), Huifang Lv, Beibei Chen, Jianzheng Wang, Xiaojing Shi, Weifeng Xu, Hong‐Min Liu, Xiaobing Chen, Zhe‐Sheng Chen, Bin Yu	24
16	Inhibition of lysine-specific demethylase 1 (LSD1) prevented tumor growth and metastasis by downregulating PD-L1 expression in lung adenocarcinoma 2022 ·Genes & Diseases ·Pengxing He, Linna Du, Hao Pan, Yang Han, Yufei Ren, (unknown), Yanli Ding, Zhao Wen, (unknown), Hong‐Min Liu	5
17	New drug approvals for 2019: Synthesis and clinical applications 2020 ·European Journal of Medicinal Chemistry ·Shuo Yuan, Bin Yu, Hong‐Min Liu	48
18	A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors 2020 ·Acta Pharmaceutica Sinica B ·Yihui Song, Min Zhao, Yahong Wu, Bin Yu, Hong‐Min Liu	24
19	Discovery of new [1,2,4] Triazolo[1,5-a]Pyrimidine derivatives that Kill gastric cancer cells via the mitochondria pathway 2020 ·European Journal of Medicinal Chemistry ·Shuai Wang, (unknown), Xiaohan Yuan, Bin Yu, Yichao Xu, Hong‐Min Liu	17
20	Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp) 2020 ·Medicinal Research Reviews ·Hang Zhang, Haiwei Xu, Charles R. Ashby, Yehuda G. Assaraf, Zhe‐Sheng Chen, Hong‐Min Liu	213

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact